Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483441 | 0.81 | ALDH1A1 (0.52) | SIGMAR1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL2469241 | 0.75 | GLA (0.52) | KMT2AALDH1A1KDM1AMAOAMEN1 | |
| SCHEMBL5437369 | 0.72 | SIGMAR1 (0.44) | SIGMAR1ALDH1A1HRH4TEAD1L3MBTL1 | |
| SCHEMBL1434919 | 0.72 | DRD2 (0.41) | TEAD1DRD2DRD3 | |
| SCHEMBL3317174 | 0.72 | HRH4 (0.39) | KMT2AALDH1A1HRH4KDM4EL3MBTL1 | |
| SCHEMBL25253156 | 0.72 | POLB (0.48) | KMT2ATEAD1KDM4EMEN1 | |
| SCHEMBL25298980 | 0.71 | TEAD1 (0.58) | SIGMAR1TEAD1KDM1AMAOA | |
| SCHEMBL13060212 | 0.70 | GPR119 (0.59) | ALDH1A1MAPTKDM4EKDM1AL3MBTL1 | |
| SCHEMBL4713876 | 0.69 | TLR2 (0.50) | SIGMAR1KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL29578733 | 0.68 | GLA (0.45) | KMT2AKDM1AMAOAMEN1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-1933830-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007007057-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | SIGMAR1 25/4885KMT2A 3099/4885ALDH1A1 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.